Agilent participates in landmark study
Agilent microarrays have been used in a landmark research study on prenatal samples.
Agilent microarrays have been used in a landmark research study on prenatal samples. The study encompassed three years and 4400 samples and was designed to evaluate the accuracy and potential advantages of using microarray analysis over conventional karyotyping. Researchers from Emory University, Baylor College of Medicine, Columbia University and Signature Genomics all took part in the study.
Most of the samples were uncultured amniotic fluid and chorionic villi and all were sent to a reference lab for chromosome analysis.
The study represents an important milestone in understanding prenatal abnormalities. Dr Laird Jackson, Professor of Genetics, Department of Obstetric and Gynecology, Drexel University College of Medicine, commented, “This landmark research study on prenatal samples will have long-lasting implications to the research community. Microarrays allowed us to detect smaller aberrations compared to traditional karyotyping.”
Seventy one percent of samples were run on Agilent SurePrint CGH microarrays and Agilent software was used for data analysis. Agilent also assisted the research group in developing the arrays used in the study.
For more information please visit ref="http://www.agilent.com">www.agilent.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
